Urinary Tract Infection Therapeutics Market Size, Share 2030

Segments - Urinary Tract Infection Therapeutics Market by Types (Quinolones, Penicillin & Combinations, Cephalosporin, Tetracycline, Sulphonamides, Nitrofurans, and Others), Indications (Complicated Urinary Tract Infection and Uncomplicated Urinary Tract Infection), and Regions (North America, Latin America, Europe, Asia Pacific and Middle East & Africa) - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast 2021 – 2028

Author : Raksha Sharma

Fact-checked by : Vineet Pandey

Editor : Vishal Golekar

Report Description

The global urinary tract infection therapeutics market size is anticipated to expand at a robust CAGR during the forecast period, 2021-2028. The growth of the market is attributed to rising awareness about the urinary tract infection. Moreover, increasing prevalence of diabetes and kidney stones are driving the market growth.

A urinary tract infection (UTI) is an infection in urinary system such as kidney, ureter, bladder, and urethra. UTIs can be caused due to various reasons, including unsafe intercourse, lack of hygiene, and diabetes. UTIs are more common in women than men due to inherent complications in the female reproductive system. According to the World Health Organization (WHO), over one million hospitalizations of women occur each year due to UTIs and it affects almost half the female population around the world.

Urinary Tract Infection Therapeutics Market Key Takeaways

UTI occurs when there is a compromise of host defense mechanism and a virulent microbe adheres, multiplies, and persists in a portion of the urinary tract. Most commonly, UTI is caused by bacteria, while fungi and viruses can also cause UTI. Urine culture is the gold standards for diagnosis of bacterial UTI.

Identifying the location of infection as well as comorbidities are essential to guide the diagnostic and therapeutic plan. Antimicrobial agents are the mainstay of therapy for bacterial UTI.

Market Trends, Drivers, Restraints, and Opportunities:

Rising number of combination drugs that are more effective than conventional ones is one of the major drivers that is contributing to the growth of the global urinary tract infection therapeutics market.
Increasing geriatric population is expected to augment the market growth.
Lack of awareness about the prevalence of UTI can restrain the growth of the market.
Rising number of government initiatives to increase the awareness about UTI can create lucrative opportunities for the industry players during the forecast period.

Scope of Urinary Tract Infection Therapeutics Market Report

The report on the global urinary tract infection therapeutics market includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have also been included in the report.

Attributes	Details
Report Title	Urinary Tract Infection Therapeutics Market - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast
Base Year	2020
Historic Data	2018–2019
Forecast Period	2021–2028
Segmentation	Types (Quinolones, Penicillin & Combinations, Cephalosporin, Tetracycline, Sulphonamides, Nitrofurans, and Others), Indications (Complicated Urinary Tract Infection, and Uncomplicated Urinary Tract Infection)
Regional scope	North America, Latin America, Europe, Asia Pacific and Middle East & Africa
Report Coverage	Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, and Trends, and Revenue Forecast
Key Players Covered in the Report	Teva Pharmaceutical Industries Ltd, Sun Pharmaceutical Industries Ltd, Mylan N.V., ALLERGAN, Pfizer Inc., Cipla Ltd, F. Hoffmann-La Roche Ltd, Shionogi Inc., Amway, and DuPont Nutrition & Biosciences

Urinary Tract Infection Therapeutics Market Segment Insights

Quinolones segment to grow at a rapid pace

Based on types, the market is divided into quinolones, penicillin & combinations, cephalosporin, tetracycline, sulphonamides, nitrofurans, and others. The quinolones segment is anticipated to account for a key share and is anticipated to grow at a robust rate during the forecast period. Quinolones is the most commonly prescribed drug type by physicians Conversely, the cephalosporin segment is expected to grow at a healthy rate in the coming years.

Urinary Tract Infection Therapeutics Market Types

Complicated urinary tract infections segment to account a major market share

Based on indications, the market is divided into complicated urinary tract infection and uncomplicated urinary tract infection. The complicated urinary tract infection segment is anticipated to account for a major share due to rising number of patients getting infected to UTI due to multidrug resistant bacteria, making it more difficult for treatment.

North America to account a considerable market share

On the basis of regions, the market is segregated into North America, Europe, Asia Pacific, Middle East & Africa, and Latin America. North America is expected to account for a considerable market share during the forecast period. Growing awareness and prevalence of UTI and increasing incidence of diabetes are driving the regional market growth. The market in Europe is expected to grow at a substantial rate owing to increased accessibility to improved healthcare facilities along with high UTI prevalence among the population.

Urinary Tract Infection Therapeutics Market Regions

Segments

The global urinary tract infection therapeutics has been segmented on the basis of

Types

Quinolones
Penicillin & Combinations
Cephalosporin
Tetracycline
Sulphonamides
Nitrofurans
Other

Indications

Complicated Urinary Tract Infection
Uncomplicated Urinary Tract Infection

Key Players

Teva Pharmaceutical Industries Ltd
Sun Pharmaceutical Industries Ltd
Mylan N.V.
ALLERGAN
Pfizer Inc.
Cipla Ltd
F. Hoffmann-La Roche Ltd
Shionogi Inc.
Amway
DuPont Nutrition & Biosciences

Competitive Landscape

The major players of the market are Teva Pharmaceutical Industries Ltd, Sun Pharmaceutical Industries Ltd, Mylan N.V., ALLERGAN, Pfizer Inc., Cipla Ltd, F. Hoffmann-La Roche Ltd, Shionogi Inc., Amway, DuPont Nutrition & Biosciences.

Companies are focusing on innovation, expansion and acquisitions to expand their market share.

Urinary Tract Infection Therapeutics Market Key Players

Table Of Content

1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Urinary Tract Infection Therapeutics Market Overview
  4.1. Introduction
     4.1.1. Market Taxonomy
     4.1.2. Market Definition
  4.2. Macro-Economic Factors
     4.2.1. Industry Outlook
  4.3. Urinary Tract Infection Therapeutics Market Dynamics
     4.3.1. Market Drivers
     4.3.2. Market Restraints
     4.3.3. Opportunity
     4.3.4. Market Trends
  4.4. Urinary Tract Infection Therapeutics Market - Supply Chain
  4.5. Global Urinary Tract Infection Therapeutics Market Forecast
     4.5.1. Urinary Tract Infection Therapeutics Market Size (US$ Mn) and Y-o-Y Growth
     4.5.2. Urinary Tract Infection Therapeutics Market Size (000â€™ Units) and Y-o-Y Growth
     4.5.3. Urinary Tract Infection Therapeutics Market Absolute $ Opportunity
5. Global Urinary Tract Infection Therapeutics Market Analysis and Forecast by Types
  5.1. Market Trends
  5.2. Introduction
     5.2.1. Basis Point Share (BPS) Analysis by Types
     5.2.2. Y-o-Y Growth Projections by Types
  5.3. Urinary Tract Infection Therapeutics Market Size and Volume Forecast by Types
     5.3.1. Quinolones
     5.3.2. Penicillin & Combinations
     5.3.3. Cephalosporin
     5.3.4. Tetracycline
     5.3.5. Sulphonamides
     5.3.6. Nitrofurans
     5.3.7. Other
  5.4. Absolute $ Opportunity Assessment by Types
  5.5. Market Attractiveness/Growth Potential Analysis by Types
6. Global Urinary Tract Infection Therapeutics Market Analysis and Forecast by Region
  6.1. Market Trends
  6.2. Introduction
     6.2.1. Basis Point Share (BPS) Analysis by Region
     6.2.2. Y-o-Y Growth Projections by Region
  6.3. Urinary Tract Infection Therapeutics Market Size and Volume Forecast by Region
     6.3.1. North America
     6.3.2. Latin America
     6.3.3. Europe
     6.3.4. Asia Pacific
     6.3.5. Middle East and Africa (MEA)
  6.4. Absolute $ Opportunity Assessment by Region
  6.5. Market Attractiveness/Growth Potential Analysis by Region
  6.6. Global Urinary Tract Infection Therapeutics Demand Share Forecast, 2019-2026
7. North America Urinary Tract Infection Therapeutics Market Analysis and Forecast
  7.1. Introduction
     7.1.1. Basis Point Share (BPS) Analysis by Country
     7.1.2. Y-o-Y Growth Projections by Country
  7.2. North America Urinary Tract Infection Therapeutics Market Size and Volume Forecast by Country
     7.2.1. U.S.
     7.2.2. Canada
  7.3. Absolute $ Opportunity Assessment by Country
  7.4. North America Urinary Tract Infection Therapeutics Market Size and Volume Forecast by Types
     7.4.1. Quinolones
     7.4.2. Penicillin & Combinations
     7.4.3. Cephalosporin
     7.4.4. Tetracycline
     7.4.5. Sulphonamides
     7.4.6. Nitrofurans
     7.4.7. Other
  7.5. Basis Point Share (BPS) Analysis by Types
  7.6. Y-o-Y Growth Projections by Types
  7.7. Market Attractiveness/Growth Potential Analysis
     7.7.1. By Country
     7.7.2. By Product Type
     7.7.3. By Application
  7.8. North America Urinary Tract Infection Therapeutics Demand Share Forecast, 2019-2026
8. Latin America Urinary Tract Infection Therapeutics Market Analysis and Forecast
  8.1. Introduction
     8.1.1. Basis Point Share (BPS) Analysis by Country
     8.1.2. Y-o-Y Growth Projections by Country
     8.1.3. Latin America Average Pricing Analysis
  8.2. Latin America Urinary Tract Infection Therapeutics Market Size and Volume Forecast by Country
      8.2.1. Brazil
      8.2.2. Mexico
      8.2.3. Rest of Latin America
   8.3. Absolute $ Opportunity Assessment by Country
  8.4. Latin America Urinary Tract Infection Therapeutics Market Size and Volume Forecast by Types
     8.4.1. Quinolones
     8.4.2. Penicillin & Combinations
     8.4.3. Cephalosporin
     8.4.4. Tetracycline
     8.4.5. Sulphonamides
     8.4.6. Nitrofurans
     8.4.7. Other
  8.5. Basis Point Share (BPS) Analysis by Types
  8.6. Y-o-Y Growth Projections by Types
  8.7. Market Attractiveness/Growth Potential Analysis
     8.7.1. By Country
     8.7.2. By Product Type
     8.7.3. By Application
  8.8. Latin America Urinary Tract Infection Therapeutics Demand Share Forecast, 2019-2026
9. Europe Urinary Tract Infection Therapeutics Market Analysis and Forecast
  9.1. Introduction
     9.1.1. Basis Point Share (BPS) Analysis by Country
     9.1.2. Y-o-Y Growth Projections by Country
     9.1.3. Europe Average Pricing Analysis
  9.2. Europe Urinary Tract Infection Therapeutics Market Size and Volume Forecast by Country
     9.2.1. Germany
     9.2.2. France
     9.2.3. Italy
     9.2.4. U.K.
     9.2.5. Spain
     9.2.6. Russia
     9.2.7. Rest of Europe
  9.3. Absolute $ Opportunity Assessment by Country
  9.4. Europe Urinary Tract Infection Therapeutics Market Size and Volume Forecast by Types
     9.4.1. Quinolones
     9.4.2. Penicillin & Combinations
     9.4.3. Cephalosporin
     9.4.4. Tetracycline
     9.4.5. Sulphonamides
     9.4.6. Nitrofurans
     9.4.7. Other
  9.5. Basis Point Share (BPS) Analysis by Types
  9.6. Y-o-Y Growth Projections by Types
  9.7. Market Attractiveness/Growth Potential Analysis
     9.7.1. By Country
     9.7.2. By Product Type
     9.7.3. By Application
  9.8. Europe Urinary Tract Infection Therapeutics Demand Share Forecast, 2019-2026
10. Asia Pacific Urinary Tract Infection Therapeutics Market Analysis and Forecast
  10.1. Introduction
     10.1.1. Basis Point Share (BPS) Analysis by Country
     10.1.2. Y-o-Y Growth Projections by Country
     10.1.3. Asia Pacific Average Pricing Analysis
  10.2. Asia Pacific Urinary Tract Infection Therapeutics Market Size and Volume Forecast by Country
     10.2.1. China
     10.2.2. Japan
     10.2.3. South Korea
     10.2.4. India
     10.2.5. Australia
     10.2.6. Rest of Asia Pacific (APAC)
  10.3. Absolute $ Opportunity Assessment by Country
  10.4. Asia Pacific Urinary Tract Infection Therapeutics Market Size and Volume Forecast by Types
     10.4.1. Quinolones
     10.4.2. Penicillin & Combinations
     10.4.3. Cephalosporin
     10.4.4. Tetracycline
     10.4.5. Sulphonamides
     10.4.6. Nitrofurans
     10.4.7. Other
  10.5. Basis Point Share (BPS) Analysis by Types
  10.6. Y-o-Y Growth Projections by Types
  10.7. Market Attractiveness/Growth Potential Analysis
     10.7.1. By Country
     10.7.2. By Product Type
     10.7.3. By Application
  10.8. Asia Pacific Urinary Tract Infection Therapeutics Demand Share Forecast, 2019-2026
11. Middle East & Africa Urinary Tract Infection Therapeutics Market Analysis and Forecast
  11.1. Introduction
     11.1.1. Basis Point Share (BPS) Analysis by Country
     11.1.2. Y-o-Y Growth Projections by Country
     11.1.3. Middle East & Africa Average Pricing Analysis
  11.2. Middle East & Africa Urinary Tract Infection Therapeutics Market Size and Volume Forecast by Country
     11.2.1. Saudi Arabia
     11.2.2. South Africa
     11.2.3. UAE
     11.2.4. Rest of Middle East & Africa (MEA)
  11.3. Absolute $ Opportunity Assessment by Country
  11.4. Middle East & Africa Urinary Tract Infection Therapeutics Market Size and Volume Forecast by Types
     11.4.1. Quinolones
     11.4.2. Penicillin & Combinations
     11.4.3. Cephalosporin
     11.4.4. Tetracycline
     11.4.5. Sulphonamides
     11.4.6. Nitrofurans
     11.4.7. Other
  11.5. Basis Point Share (BPS) Analysis by Types
  11.6. Y-o-Y Growth Projections by Types
  11.7. Market Attractiveness/Growth Potential Analysis
     11.7.1. By Country
     11.7.2. By Product Type
     11.7.3. By Application
  11.8. Middle East & Africa Urinary Tract Infection Therapeutics Demand Share Forecast, 2019-2026
12. Competition Landscape
  12.1. Global Urinary Tract Infection Therapeutics Market: Market Share Analysis
  12.2. Urinary Tract Infection Therapeutics Distributors and Customers
  12.3. Urinary Tract Infection Therapeutics Market: Competitive Dashboard
  12.4. Company Profiles (Details: Overview, Financials, Developments, Strategy)
     12.4.1. Teva Pharmaceutical Industries Ltd
     12.4.2. Sun Pharmaceutical Industries Ltd
     12.4.3. Mylan N.V.
     12.4.4. ALLERGAN
     12.4.5. Pfizer Inc.
     12.4.6. Cipla Ltd
     12.4.7. F. Hoffmann-La Roche Ltd
     12.4.8. Shionogi Inc.
     12.4.9. Amway
     12.4.10. DuPont Nutrition & Biosciences